Background. There are plans to introduce the oral rotavirus vaccine Rotarix (GlaxoSmithKline), 1 of 2 recently developed vaccines against rotavirus, in Peru.
children do not receive adequate replacement of fluids and die from the shock caused by severe dehydration.
There are plans to introduce the oral rotavirus vaccine Rotarix (GlaxoSmithKline), 1 of 2 recently developed vaccines against rotavirus, in Peru. Because of the high price of this vaccine ($15 per course when introduced in Brazil and Panama [2] ), it is important to consider its likely public health impact and costeffectiveness.
One important feature of a rotavirus vaccine program is the extent to which vaccines are administered at the recommended ages. Children often receive vaccines later than the target age, and similar delays for rotavirus vaccine can be expected because the vaccine will need to be accommodated within the existing schedule. These delays can lead to prolonged periods without protection, reducing the public health impact of the rotavirus vaccine program. In addition, the World Health Organization (WHO) currently recommends that the rotavirus vaccine series should not be initiated for infants 112 weeks of age, because there is insufficient information on safety in older infants [3, 4, 5] . 
METHODS
Model framework. A static cohort model was used to produce the cost-effectiveness estimates. Figure 1 shows the structure of the model. For each successive birth cohort during the period 2009-2024, projections of life-years lived of 1-59 months [6] were multiplied by the incidence of disease among children to give the total number of rotavirus gastroenteritis cases expected to occur by the time the children are 5 years of age. Cases were then distributed into subgroups classified by age and severity. In Peru, the child mortality rate in rural areas is approximately twice the urban rate; thus, urban and rural areas were modeled separately [7] . The numbers of incident cases were reduced by vaccine efficacy and estimates of vaccination coverage at 12 weeks of age and at 6, 9, 12, 24, 36, and 48 months of age. The number of cases determined the number of outpatient visits, inpatient admissions, and deaths.
The model evaluates the incremental costs and effects of introducing the vaccine, compared with not introducing it. Cost savings resulting from reductions in the number of outpatient visits and inpatient admissions were subtracted from the costs of the vaccination program. The primary outcome measure was the cost per disability-adjusted life-year (DALY) averted, based on numbers of rotavirus cases (severe and nonsevere) and deaths due to rotavirus disease. Costs are shown in 2006 US dollars, with ratios presented in both discounted (3% costs and effects) and undiscounted form. DALY age weights were used in the base-case scenario and were removed in scenario analysis. Cost-effectiveness ratios were based on the cumulative future costs and effects attributed to children born during 2009-2024. This time series allows investigation of trends in births, urbanization, and rotavirus-associated mortality and can be a useful way to investigate the impact on cost-effectiveness of trends in diarrhea-associated mortality, vaccine coverage, and price. The model was developed in Excel (Microsoft).
Cases. The incidence of rotavirus gastroenteritis was assumed to be 0.13 episodes per child aged !5 years per year. This incidence was based on a review of the rotavirus burden in Peru that analyzed a limited number of community studies of incidence of diarrhea and the proportion of episodes of diarrhea attributable to rotavirus, as determined by testing of stool samples [8] .
We assumed that 26% of rotavirus gastroenteritis episodes would ultimately progress to severe symptoms, defined as a Vesikari severity score у11 [9] . This was the reported fraction of all-cause gastroenteritis episodes that were severe in the placebo group of a vaccination trial conducted in urban areas in Brazil, Venezuela, and Mexico [10] . The figure is lower than the proportion of rotavirus gastroenteritis episodes classified as severe in the same trial, but a community surveillance study from Lima that involved 2500 children aged !2 years suggests that rates of both all-cause and rotavirus dehydrating diarrhea may be lower than observed during this trial. We therefore used the all-cause diarrhea severity fraction reported in the trial on the basis that the severity fraction for rotavirus diarrhea would not be lower than this value, even in Peru, where a lower proportion of severe cases has been observed. Severity may be higher in rural areas, where there is more-limited access to rehydration treatment; thus, we assumed that severe cases accounted for 17% of urban episodes and 43% of rural episodes. The Demographic and Health Surveys (DHS) reported the urban-to-rural ratio of mortality among children !5 years of age to be 0.4 [7] . This ratio was used as a proxy for the urban-torural ratio of the percentage of cases of rotavirus disease that were severe.
The mean duration of illness was assumed to be 6 days for all cases of rotavirus gastroenteritis, irrespective of severity [11] . A disability weight of 0.119 was used for nonsevere cases of rotavirus gastroenteritis on the basis of WHO expert panel estimates [12] . A weight of 0.518 was used for severe cases of rotavirus gastroenteritis on the basis of the reported disutility of hospitalization for gastrointestinal disorders [13] .
Deaths. According to a recent community-based survey in Peru, there were 50 deaths due to diarrhea per 100,000 children aged !5 years, with rates ranging from 203 in regions of the Amazon to 12 in the urban coastal areas of Lima [14] . This is ∼6% of the total number of deaths among children !5 years of age that were reported during the same period. In 2002, the Pan American Health Organization estimated that diarrhea contributed 3.5% of the total number of registered child deaths [15] . Both estimates are markedly less than those from earlier studies [16, 17] .
Studies from the National Children's Hospital in Lima in 1987, 1991, and 1997 identified rotavirus in stool samples from 28%, 32%, and 52%, respectively, of children aged !5 years who were admitted to the hospital with severe gastroenteritis, and this led researchers to conclude that rotavirus is responsible for a similar percentage of overall diarrhea-related deaths among children [18] [19] [20] . For the base-case scenario, we used the median estimate of 32%, which is in line with the mean of 13 hospital studies reported in an earlier review [8] . Applying this figure to the annual 50 diarrhea-related deaths per 100,000 children !5 years of age gives a rate of 16 deaths due to rotavirus disease per 100,000 children aged !5 years. This figure is 2% of the mortality rate among children !5 years of age during the same period (ie, 1 in 1265 newborns die of rotavirus disease before 5 years of age). This rate lies between the rate (1 death among 642 newborns) estimated using recently published WHO rotavirus-associated mortality rates for Peru [21] and the estimate (1 death among 1554 newborns) by Rheingans et al [22] for 8 Latin American countries combined.
Projected deaths due to rotavirus disease among children aged !5 years during each year were divided into age groups based on recently published WHO global estimates [23] : 3.2% among children aged !3 months, 11.6% among children aged 3-5 months, 18.9% among children aged 6-8 months, 22% among children aged 9-11 months, 22.1% among children aged 12-23 months, and 22.2% among children aged у24 months. We assumed the same age distribution for both cases and deaths.
Hospital visits and admissions. Of children surveyed in the DHS national household survey from July through November 2000, 15.4% were reported to have had an episode of diarrhea at some time during the previous 2 weeks. From these data, we estimated that 397 outpatient visits per 1000 cases occurred (422 urban; 375 rural), irrespective of severity; exclusion of visits to the private sector and of the social insurance (Peruvian National Social Security System) scheme reduced the rate to 291 visits per 1000 cases (240 urban; 339 rural). For hospitals, it was assumed, on the basis of the mean proportion of diarrhea cases requiring hospitalization in government facilities in Lima, that 22% of the health care contacts in the survey were inpatient admissions [8] . We estimated that there were 151 inpatient admissions (214 urban; 92 rural) for every 1000 severe episodes of gastroenteritis (Vesikari severity score, у11). On the basis of DHS estimates, 79% of these hospitalizations were estimated to have occurred in Government hospitals, with the remainder occurring in private hospitals and Peruvian National Social Security System hospitals.
The same rates of outpatient visits were used for nonsevere and severe cases of rotavirus gastroenteritis; visits were distributed across 10 outpatient settings, according to the reported distribution in the DHS (Table 1) . It was assumed that only patients with severe disease could become inpatients, with admissions distributed across 5 inpatient settings, according to the reported distribution in the DHS. Expert consensus panels of public health professionals and medical practitioners were asked to estimate the percentages of secondary or tertiary care contacts for diarrhea that were seen at tertiary care hospitals. The median value was 0.9% (1.2% for urban children; 0% for rural children).
Treatment costs. Data on the costs borne by the government for providing care to patients with diarrhea were collected from January through December 2002. Costs borne by patients, their families, and informal caregivers in accessing these services were collected from January through December 2003. Costs arising from activity in the private sector and by the Peruvian National Social Security System social insurance scheme were excluded, as were any costs borne by households in accessing these services.
Facilities from 3 of the 24 Peruvian regions were selected to reflect the 3 geographical types: Lima (the coast), Ayacucho (the mountains), and San Martin (the jungle). Standard costing methods were used at 19 facilities ( Table 2 ). Government facilities were grouped into clinics and primary, secondary, and tertiary care hospitals. All costs were inflated to 2006 Peruvian soles with use of the World Bank gross domestic product deflators [24] and were then converted to 2006 US dollars with use of a mean exchange rate of US $1.00 to 3.36 soles [25] . Weighted means of cost and duration of hospital stay were generated to reflect the proportions of the population living in coastal (52%), mountain (36%), and jungle (12%) regions, based on DHS survey estimates.
Estimated costs are presented in table 1.
Step-down costallocation methods were used to estimate hotel costs per bedday. Costs of drugs, procedures, and duration of hospital stay that were associated with diarrhea were collected through a retrospective review of inpatient records ( ). Cases ren p 30 corded as involving either some or severe dehydration were categorized as severe cases of rotavirus gastroenteritis. Diarrhea without dehydration was categorized as nonsevere rotavirus gastroenteritis. The records system in Peru does not classify visits to outpatient departments and health centers by disease; thus, the mean cost of an outpatient visit (without the cost of drugs) was estimated and supplemented by additional data from physician interviews ( ) about drugs dispensed for n p 49 treatment of diarrhea. Data on the household costs of outpatient visits (out-of-pocket expenditure and indirect costs borne by families and caregivers when accessing government outpatient services) were collected using structured interviews ( ). Household costs associated with an inpatient stay n p 33 were estimated by multiplying the outpatient household cost by 2.5 on the basis of the ratio reported by Rheingans et al [22] for Venezuela.
Vaccination coverage and timing scenarios. We evaluated 3 different scenarios for the timing of administration: (1) strictly according to schedule, at 2 and 4 months of age (on time); (2) distributed around the scheduled date in the same way as actual timing in the program (flexible); and (3) flexible but assuming vaccination is not initiated for infants aged 112 weeks (restricted). The age-specific coverage rates used for the Assume 50% of the household cost in a goverment primary care hospital, when data were unavailable for a government clinic.
c Assume the sum of the mean cost in a government primary care hospital and a government tertiary care hospital, when data were unavailable for a government secondary care hospital.
d
The cost in an outpatient household was multiplied by 2.5, based on the ratio reported by Rheingans et al [22] for Venezuela ($13.76 for the household cost of an IPD admission vs $5.65 for the household cost of an OPD visit). The duration of hospital stay was 2.86 days at government primary care hospitals, 2.92 days at government secondary care hospitals, and 4.60 days at government tertiary care hospitals. flexible scenario were based on a survival analysis with use of data on age at vaccination from the 2000 Peruvian DHS [6] . In Peru, Rotarix would be given together with the first and third doses of the diphtheria, tetanus, and pertussis (DTP) vaccine, at 2 and 4 months of age. Coverage for the first dose of DTP vaccine in Peru was estimated to be 97% during 1999-2000 [26] but has fluctuated since then. We assumed that coverage of the first dose of the DTP vaccine would remain constant at 97% once fully integrated into the Expanded Program of Immunization (EPI). For logistic, financial, and political reasons, it may be necessary to gradually phase rotavirus vaccine into the existing EPI. On the basis of the precedent set by the recent introduction of Haemophilus influenzae type b vaccine, we assumed that national rotavirus vaccine dose 1 coverage rates would be 21%, 41%, 64%, 69%, and 96.7% during the first 5 years and 97% thereafter. These national estimates were based on DHS reported coverage of the first dose of DTP vaccine, by region, among children aged 12 months [6] and reflects 8 regions during the first year, 13 during the second, 20 during the third, 23 during the fourth, and all 25 by the fifth.
We assumed that the difference between coverage for the first and second doses of rotavirus vaccine would reduce by 5% annually. This is more conservative than the annual improvement in coverage reported for the DTP vaccine in the 2 recent DHS surveys. Reported differences between rural and urban coverage for doses 1 and 2 were based on the DHS estimates for the first and third doses of the DTP vaccine [6] . We assumed that the rotavirus vaccine dose 2 coverage would be 93% during 2009 (96% in urban areas; 85% in rural areas) and increase to 95% (97% in urban areas; 90% in rural areas) by 2024.
Vaccine efficacy. An efficacy trial involving 2155 infants in Brazil, Mexico, and Venezuela during 2001-2002 reported 86% efficacy against severe rotavirus gastroenteritis (Vesikari severity score, у11) and 70% efficacy against rotavirus gastroenteritis of any severity [10] . A subsequent large trial involving 20,169 infants from 11 Latin American countries during 2003-2004 reported 84.8% efficacy against severe rotavirus gastroenteritis (Vesikari severity score, у11) and 84.7% against episodes considered to be severe on the basis of clinical case definitions [27] . Another more recent trial in Latin America also demonstrated vaccine efficacy of 80.5% against severe rotavirus disease after a mean duration of follow-up of 20 months [28] .
We assumed efficacy of 85% against severe disease with 2 doses of vaccine. Using a reported efficacy against rotavirus gastroenteritis of any severity of 70%, we estimated an efficacy against nonsevere disease of 65%. Evidence from the Rotarix trial in 3 Latin American countries highlighted a similar antibody response after 1 and 2 doses, and other rotavirus vaccines have reported high vaccine protection after the first dose [1, 29, 30] ; these findings suggest that the first dose of Rotarix is also likely to be protective. The efficacy of a single dose has recently been reported as 89.8% (95% confidence interval, 8.9%-99.8%) against any episode of rotavirus gastroenteritis [31] . However, because this figure was based on a very short follow-up period (∼2 months), we assumed 75% protection against severe disease with 1 dose and 57% efficacy against nonsevere disease with 1 dose.
Costs of vaccination. The introductory vaccine price of US $7.50 per dose was based on 2008 Pan American Health Organization revolving fund prices [32] . Incremental vaccination costs, based on coverage level, included the cost of the vaccine itself and the cost of administration of the vaccine, namely the cost of additional staff, training, cold chain maintenance, storage space, and social mobilization. Because the rotavirus vaccine will be administered according to the existing schedule for DTP doses 1 and 3, these incremental administrative costs are assumed to be low; we assumed an incremental administration cost of US $0.50 per dose, including wastage [33] . Because of the safety profile of the vaccine in the large trial in 11 Latin American countries, no costs for adverse events were included.
In the base-case scenario, we assumed a 5% annual decrease in the vaccine price per dose, from $7.50 to $3.30, during 2009-2024. However, because the future price of the vaccine is highly uncertain, we also evaluated a scenario with no decrease in price over time. Figure  2 ). These vaccination costs are set against total treatment cost savings of US $19 million (US $25 million undiscounted), with a mean discounted annual savings over the period of ∼US $1 million per year; 77% of the cost savings would be to the government health providers, and the remaining 23% would be to the families who access those services. Table 4 presents a 1-way sensitivity analysis of incremental costs per DALY averted to adjustments in base-case parameters of ‫.%01ע‬ The parameters with the greatest influence on results were rotavirus-associated mortality, vaccine efficacy against severe disease, and vaccination price. The discounted costs per DALY averted for restricted, flexible, and on-time schedules were $621, $615, and $581, respectively. Equivalent undiscounted costs were $244, $242, and $228, respectively. For each of the 3 scenarios, effectiveness in reducing deaths was 53%, 66%, and 69%, respectively. In the rural areas, mortality was higher and the program was more cost-effective than in the urban areas. However, because the coverage among children aged 12 weeks was lower in rural areas than in urban areas, a restricted policy tilted the balance of expenditure on the program toward the less cost-effective urban areas and made the restricted scenario slightly less cost-effective overall than the flexible scenario.
The effects of select changes in assumptions on the results are shown in table 5. This included the assumption that casefatality ratios remain constant over time, rather than decreasing with overall trends in mortality among children !5 years of age, shorter periods of evaluation, and a pessimistic pricing scenario, which assumed no decrease in price over time. A single-dose strategy was also evaluated. The discounted cost per DALY averted in these additional scenarios ranged from $229 (assuming a 1-dose schedule administered on time) to $1491 (assuming half the baseline vaccine efficacy rates and a restricted timing policy). The percentage change in the number of deaths prevented between the base-case scenario and each scenario evaluated for the period 2009-2024 ranged from Ϫ56% for a 1-dose schedule using half the base-case vaccine efficacy to 190%, under the assumption that rotavirus accounts for 3.8% of mortality among children aged !5 years (ie, 52% of diarrhea-associated mortality), as recently estimated by the WHO [21] .
DISCUSSION
The Commission for Macroeconomics and Health considers any intervention with a ratio lower than the gross national income per capita to be highly cost-effective; this view is endorsed by the WHO [34] . On the basis of a reported 2006 gross national income per capita of US $2920 (US $3990 in 2008) [35] , a rotavirus vaccination program would be considered to be highly cost-effective in Peru. The most cost-effective scenario would be to administer only 1 dose of the vaccine; however, this would avert ∼10% fewer deaths than a 2-dose strategy and requires further investigation, because it is highly dependent on our untested and possibly optimistic assumption about the efficacy of 1 dose of Rotarix.
Our results are within the range of rotavirus vaccine costeffectiveness results estimated for 8 Latin American and Caribbean countries [33] . At a cost of US $24 per course (for a 2-dose vaccine), the authors estimated that the incremental cost per DALY averted would range from $269 in Honduras to $10,656 in Chile. Our results are also of a similar order of magnitude to those estimated by Constenla et al [36] in 2007 for a pneumococcal vaccine in Latin America and the Caribbean; the authors estimated that the cost per DALY averted could range from $129 (assuming $5 per dose) to $5106 (assuming $53 per dose).
During 2006, ∼5% (US $36 million) of the Ministry of Health's budget was spent on immunizations (M. A. Mendoza, personal correspondence). Our estimates of annual cost fluctuate over time because of changes in coverage, the number of births, child mortality, and price, but the mean annual cost for the period is ∼US $5 million per year (US $4 million discounted). This estimate would represent a 10%-15% increase in immunization spending based on the 2006 budget. We estimate that these costs would be offset by ∼US $1.4 million (US $1.1 million discounted) in cost savings per year; 23% of these savings would be to the families who access government services.
We estimate that the percentage of rotavirus-associated deaths averted by the rotavirus vaccine program would decrease from 66% to 53%, if safety recommendations are strictly observed. The safety recommendations are designed to avoid any increased risk of adverse events among infants vaccinated at older ages. A previous vaccine, RotaShield (Wyeth-Ayerst), was withdrawn from the market following a reported increase in the risk of intussusception, a rare bowel disorder, when administered to older infants. However, no such association has yet been found with new rotavirus vaccines; thus, we did not include increased risks and costs of adverse events in our flexible vaccination scenario. It is difficult to know whether this is a valid assumption, because children in clinical safety trials receive the vaccine within the recommended age window. However, it has been argued that, even if the risk of such complications were material, the benefit of averting death due to rotavirus disease may outweigh the risk in settings with high rotavirus-associated mortality rates [37] .
We used conservative estimates of rotavirus-associated mortality (2% of the mortality rate among children aged !5 years, rather than 3.8%, as estimated by the WHO). In addition, we used a static model with no allowance for indirect benefits attributable to reduced shedding in the community [38] . Health care use rates were based on DHS estimates, which are prone to underestimation because some children may not receive care for illnesses reported until after the survey. However, these rates for diarrhea should provide at least a conservative proxy for care-seeking associated with rotavirus gastroenteritis. Our estimates of the inpatient cost per bed-day (US $13-$53 during , after adjustment for inflation. Estimates for outpatient visit costs ($2-$5) were also comparable. One of the 8 United Nations Millennium Development Goals is to reduce the mortality rate among children !5 years of age by two-thirds during 1990-2015. From 1990 through 2006, the mortality rate among children aged !5 years in Peru decreased from 78 to 25 deaths per 1000 live births, a 68% reduction [39] . There remains, however, a stark difference in mortality rates among children aged !5 years between rural and urban areas, and the official status of the target is "possible to achieve if some changes are made" [40] . We estimate that rotavirus vaccination could reduce mortality among children aged !5 years by at least 1%, once it is fully established in the EPI.
On the basis of current WHO guidelines and conservative assumptions, rotavirus vaccination in Peru is highly cost-effective. However, a policy to withhold the vaccine from children aged 112 weeks of age would reduce its impact on rotavirusrelated deaths from 66% to 53%. If considered to be affordable and cost-effective, rotavirus vaccine could provide a valuable stimulus for improving adherence to the EPI schedule and help to protect infants as early in life as possible.
